Explore the details of the Indivior Inc. V. Lupin Inc. case under case number 1:25cv00757 involving a cause of action for Patent Infringement. Review key information about the parties involved, the patents in question, and the docket entries.

Case Details

Case Number
1:25cv00757
Filing Date
Jun 20, 2025
Cause of Action
Patent Infringement
Status
-
Case Link
View Case
Nature of Suit
Patent - Abbreviated New Drug Application(ANDA)

The following parties are involved in this case, with their respective legal representatives for the case.

NameRepresented By
Indivior Inc. -
Lupin Inc. -

Patents Involved in the Case

This case involves 3 patents, each of which is central to the dispute. These patents may be subject to claims of infringement, challenges to their validity, or other issues concerning their scope and enforcement.

Application NumberPatent Number
-US11458091B2
-US12290596B2
-US4715387B2

Docket Entries

The Docket Entries section provides a chronological list of all significant filings and court actions in this case.

DateDocket EntryType

Set alerts for critical docket entry

Jun 20, 2025Summons Issued as to Lupin Inc. on 6/20/2025; Lupin Limited on 6/20/2025; Lupin Pharmaceuticals, Inc. on 6/20/2025. (Attachments: # 1 Summons Issued, # 2 Summons Issued)(mrr) (Entered: 06/20/2025)PACER Document
Jun 20, 2025Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Indivior Finance LLC, Other Affiliate Indivior PLC, Other Affiliate Indivior Global Holdings Limited, Other Affiliate Indivior US Holdings Inc., Other Affiliate RBP Global Holdings Limited for Indivior Inc. filed by Indivior Inc. (mrr) (Entered: 06/20/2025)PACER Document
Jun 20, 2025Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 11,458,091 B2; 12,290,596 B2. (mrr) (Entered: 06/20/2025)PACER Document
Jun 20, 2025Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 05/09/2025. Date of Expiration of Patent: U.S. Patent No. 11,458,091 expires July 10, 2038 and U.S. Patent No. 12,290,596 expires on August 4, 2042.Thirty Month Stay Deadline: 11/9/2027. (mrr) (Entered: 06/20/2025)PACER Document
Jun 20, 2025Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (mrr) (Entered: 06/20/2025)PACER Document
Jun 20, 2025COMPLAINT for Patent Infringement against Lupin Inc., Lupin Limited, and Lupin Pharmaceuticals, Inc. (Filing fee $ 405, receipt number ADEDC-4715387) - filed by Indivior Inc. (Attachments: # 1 Exhibits A-B, # 2 Civil Cover Sheet)(mrr) (Entered: 06/20/2025)PACER Document